Eflornithine and AMXT 1501 for Advanced Childhood Cancers
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Patient must be 26 years old or younger at the time of diagnosis.
- Must have one of these cancers that has come back or not responded to treatment: high-risk neuroblastoma, ETMR, ATRT, Ewing sarcoma, or osteosarcoma. Or have newly diagnosed DIPG.
- Must be able to swallow capsules whole.
- Must be in fairly good health (able to do most daily activities) and have adequate heart, kidney, liver, and blood cell function.
- Must have recovered from the side effects of prior cancer treatments, and certain waiting periods since last therapy apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
This trial studies a drug called DFMO for children and young adults with certain rare cancers that have not responded to standard treatments or have come back. DFMO may help stop cancer cells from growing.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
Hear when a new Atypical Teratoid/Rhabdoid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.